Trial Summary
What is the purpose of this trial?
The goal of this behavioral research study is to compare two different forms of relaxation programs that will include stretching and relaxation techniques, in order to learn if and how well they may help to improve physical and emotional well-being. This will be tested in patients with breast cancer who are receiving radiation therapy. For comparison purposes, there will also be a group of participants that does not take part in the relaxation programs. This is an investigational study. The relaxation programs are being compared for research purposes only. An "assessment" is any time you complete a set of scheduled activities for this study, such as tests and questionnaires. Up to 700 patients will take part in this study. All will be enrolled at MD Anderson.
Research Team
Lorenzo Cohen
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for women aged 18 or older with stage 0 - III breast cancer, who are about to start daily radiation therapy for 4-6 weeks. Participants must be able to communicate in English or Spanish. It's not open to those who've practiced yoga recently, have significant mobility issues, major psychiatric conditions like schizophrenia or bipolar disorder, or haven't had surgery for their cancer.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Relaxation Program (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
Dr. Peter WT Pisters
M.D. Anderson Cancer Center
Chief Executive Officer since 2017
MD from University of Western Ontario
Dr. Jeffrey E. Lee
M.D. Anderson Cancer Center
Chief Medical Officer
MD from Stanford University School of Medicine
National Institutes of Health (NIH)
Collaborator
Dr. Jeanne Marrazzo
National Institutes of Health (NIH)
Chief Medical Officer
MD from University of California, Los Angeles
Dr. Jay Bhattacharya
National Institutes of Health (NIH)
Chief Executive Officer
MD, PhD from Stanford University
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School